Human papillomavirus vaccination update

Nonavalent vaccine and the two-dose schedule

Julia ML Brotherton

THIS YEAR, 2018, is the 12th year of human papillomavirus (HPV) vaccine delivery as part of the National Immunisation Program in Australia. Australia’s ‘big bang’ approach, with a large-scale catch-up program using the quadrivalent HPV vaccine (trade name Gardasil) initially offered to all females aged 12–26 years, has since been shown to be highly effective. Males have also been offered vaccination since 2013, with an initial catch-up program to age 15 years. Protection is believed to be antibody-mediated, with vaccine-generated antibodies at very low levels able to block a conformational change the virus needs to make in order to enter the basal epithelial cell.1 Substantial declines in the incidence of genital warts (caused by HPV 6 and 11),2 vaccine-targeted HPV infections (6, 11, 16 and 18)3 and cervical pre-cancers4 have been documented, with linked registry data showing vaccine effectiveness.5 Recently, a decrease in new cases of juvenile-onset recurrent respiratory papillomatosis, a disease caused by vertical transmission of HPV 6 and 11, has also been observed.6

High, and recently increasing, HPV vaccine coverage in the routinely vaccinated cohorts (age 12–13 years, first year of high school in most states and territories) indicates the acceptability of the school-based immunisation approach. Vaccine coverage from the three doses respectively at age 14–15 years in 2016 is 87/85/79% in females and 83/80/74% in males.7 General practice plays an important part in HPV vaccination in Australia, specifically in immunising those who do not wish to, or cannot, be immunised at school and in catching up those who missed doses in the school program, with catch-up now funded up to the age of 19 years. Provider endorsement is known to be a powerful motivator for HPV vaccination, as for other vaccines. In this article, we bring general practitioners (GPs) up to date with the evidence supporting the use of the nonavalent HPV vaccine (trade name Gardasil 9) and the two-dose schedule for HPV vaccines.

Nonavalent HPV vaccine: Purpose

The nonavalent HPV vaccine was developed to extend the protection offered by the vaccine from HPV 6 and 11, which cause genital warts, and HPV 16 and 18, which are the most oncogenic types, to include the next five most frequently detected oncogenic HPV types in cervical cancers (Table 1). HPV 16 is the most oncogenic HPV type, predominating across all HPV-related cancer sites (approximately 61% cervical [higher proportion at younger ages], 81% anal, 59% vaginal, 68% vulval, 69% penile and 82% oropharyngeal HPV-related cancers).8–11 Thus, maintenance of strong protection against HPV 16 is of utmost importance when extending vaccine protection to other types. HPV 18 is the second most common type across all cancers but is as frequent as HPV 16 in cervical adenocarcinomas.12 The additional five types added (HPV 31, 33, 45, 52, 58) are each responsible for a few
per cent of cervical cancers; cumulatively, however, the overall protection against cervical cancer afforded by protection against HPV 16, 18, 31, 33, 45, 52 and 58 is estimated at 89% globally. A recent Australian study of 847 cervical cancers estimated the protection in Australia may be as high as 93% (77% HPV 16, 18 and 16% HPV 31, 33, 45, 52, 58).

**Composition**

The nonavalent vaccine is manufactured similarly to the quadrivalent vaccine. It contains virus-like particles (VLPs) for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, with an increased amount for types 16, 18 and 6, compared with the quadrivalent vaccine. The VLPs consist of the HPV outer coat protein L1 and self-assemble into particles following recombinant expression in a yeast vector system. The vaccine uses the same aluminium adjuvant as the quadrivalent vaccine but in a greater amount. The increase in VLP and aluminium concentration is to ensure the maintenance of effective protection against the quadrivalent HPV types while increasing protection to include the five additional types.

**Efficacy and immunogenicity**

A randomised controlled trial of over 14,000 women aged 16–26 years in 18 countries found that three doses of the nonavalent HPV vaccine (at zero, two and six months) provided 97% efficacy against HPV 31/33/45/52/58-related high-grade cervical, vulvar and vaginal intraepithelial neoplasia when administered to women not previously infected with those types. The comparator group in the study received the quadrivalent vaccine – given its proven efficacy, use of a placebo would have been unethical. Protection against HPV 6, 11, 16 and 18 was confirmed by demonstration that the antibody titres generated by the two vaccines were equivalent.

Immunobridging from females to males aged 16–26 years has been established in two studies. Both found equivalent antibody titres in heterosexual males. Among 300 men who have sex with men (MSM), although seroconversion rates remained over 99%, antibody titres were noted to be lower. The clinical significance of this, if any, is not known.

**Two-dose schedules**

The surprisingly strong immunogenicity of HPV vaccines, which are non-live, subunit vaccines, led to evaluation of effectiveness when administered in only two doses (i.e. a more widely spaced prime-boost effect rather than a prime-prime-boost pattern). Studies have shown that the immunogenicity of the HPV vaccines, when administered using two doses spaced 6–12 months apart to adolescents aged ≤14 years at first dose, is equivalent to that achieved using three doses of vaccine in adult women. In 2014, the World Health Organization (WHO) recommended the routine use of two-dose HPV vaccine schedules for younger adolescents, but those aged ≥15 years and those who are immunocompromised still require three doses. Randomised trials are currently underway to assess whether even one dose of HPV vaccine may be effective.

The nonavalent HPV vaccine has been evaluated in a trial comparing antibody responses in adolescents aged 9–14 years receiving two doses six or 12 months apart with responses seen in women aged 16–26 years receiving three doses.

**Table 1. Comparison of human papillomavirus vaccines**

<table>
<thead>
<tr>
<th>Bivalent HPV vaccine (Cervarix)</th>
<th>Quadrivalent HPV vaccine (Gardasil)</th>
<th>Nonavalent HPV vaccine (Gardasil 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>L1 virus-like particle types</strong></td>
<td>HPV 16, 18</td>
<td>HPV 6, 11, 16, 18</td>
</tr>
<tr>
<td><strong>Adjuvant</strong></td>
<td>ASO4 (0.5 mg aluminium hydroxide and 50 µg 3-O-desacyl-4”-monophosphoryl lipid A [MPL])</td>
<td>0.225 mg aluminium hydroxypophosphate sulphate</td>
</tr>
<tr>
<td><strong>Expression system</strong></td>
<td>Baculovirus-insect cell</td>
<td>Yeast</td>
</tr>
<tr>
<td><strong>Cross-protection</strong></td>
<td>High against HPV 31, 33, 45, 52, 56</td>
<td>Limited; some against HPV 31</td>
</tr>
<tr>
<td><strong>Registered for use in males</strong></td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Schedule</strong></td>
<td>Two doses spaced 6–12 months apart for those aged 14 years and under at first dose</td>
<td>Three doses spaced at zero, two and six months for those aged 15 years and over at first dose and immunocompromised individuals with select major medical conditions*</td>
</tr>
</tbody>
</table>

* Those who should receive a three-dose schedule include individuals with the following major medical conditions: primary or secondary immunodeficiencies (B-lymphocyte antibody and T lymphocyte complete or partial deficiencies), human immunodeficiency virus infection, malignancy, organ transplantation or significant immunosuppressive therapy (excluding asplenia or hypospadias). The recommendation for a three-dose schedule does not apply to children aged ≤14 years with asplenia, asthma, chronic granulomatous disease, chronic heart/liver/lung/renal disease, central nervous system anatomic barrier defects (eg cochlear implant), complement deficiency, diabetes or sickle cell disease, in the absence of any of the above conditions.

HPV, human papillomavirus
Antibody titres to all nine types were non-inferior (and were, in fact, higher at younger ages).

**HPV vaccine safety**

Since 2006, HPV vaccines have been used globally in over 270 million doses and scrutinised by routine surveillance systems and high-quality population-based studies assessing potential vaccine safety signals. There is no evidence that any serious illness occurs more commonly in vaccinated than unvaccinated individuals, including autoimmune and neurological conditions. The WHO Global Advisory Committee on Vaccine Safety has reviewed the vaccines seven times and continues to find them safe.

Trial data indicate a higher rate of injection site reactions (any pain, swelling, redness) in young women receiving the nonavalent vaccine than in those receiving the quadrivalent vaccine (91% vs 85%). This may be attributable to the increased amount of adjuvant. There was no difference in rates of systemic or serious adverse events. Rates of injection site reactions to the nonavalent vaccine are lower in males and in adolescents aged 9–14 years than in adult women.

**Australian program**

In 2018, the nonavalent HPV vaccine, in two doses spaced 6–12 months apart for the routine school age cohort (usual age 12–13 years), is the vaccine and schedule in use in the national program. School-based immunisation programs operate in every state and territory and require parental consent to vaccinate the child at school. In some jurisdictions, GPs are routinely involved in catching up doses missed in the school program. All GPs may be involved in providing HPV vaccine to those with special needs, immunocompromise or vaccine hesitancy, or as catch up to those aged up to 19 years, now that HPV vaccine availability for catch up has been extended (since July 2017). GPs may also proactively discuss elective HPV vaccination in those who are not funded under the national program but in whom vaccination is recommended or may be of particular benefit.

**Higher risk groups**

HPV vaccine is recommended but not funded for immunocompromised individuals and for MSM. No age limit is set on these recommendations. MSM have a markedly elevated risk of anal cancer and HPV infection, and re-infection with HPV is common. The epidemiology of HPV infection is different in males and females, with HPV infection rates in males consistent throughout life, probably because of a low likelihood of males generating protective immunity through natural infection.

The vaccine may be of benefit to prevent re-infection and spread in the anal canal regardless of previous exposure. The three-dose vaccine is also recommended for immunocompromised individuals, who may be at higher risk of HPV-related disease and cancers. Immunocompromised individuals include those with the following major medical conditions: primary or secondary immunodeficiencies (B lymphocyte antibody and T lymphocyte complete or partial deficiencies), human immunodeficiency virus infection, malignancy, organ transplantation or significant immunosuppressive therapy (but not asplenia or hyposplenia), human immunodeficiency virus infection, malignancy, organ transplantation or significant immunosuppressive therapy (but not asplenia or hyposplenia). The recommendation for a three-dose schedule does not apply to children aged ≤14 years with asplenia, asthma, chronic granulomatous disease, chronic heart, liver, lung or renal disease or central nervous system anatomical barrier defects (eg cochlear implant), complement deficiency, diabetes or sickle cell disease, in the absence of any of the above conditions.

The vaccine should also be considered for women who have undergone treatment for cervical intraepithelial neoplasia. Women in this group have shown an inability to clear HPV infection and have a long-term elevated risk of cervical cancer. While the vaccine cannot treat existing infection or disease, there is some evidence that, by stimulating protective levels of antibodies, it may prevent re-infection and subsequent disease with either the same type of HPV that caused the lesion or another type.

Women with a single positive cervical screening test (ie positive for HPV 16 and 18 or other oncogenic HPV types) have a current HPV infection that may be either an acute infection or a persisting infection. Vaccination will not alter the course of the current infection but, as for any woman, could prevent future infections with vaccine-covered HPV types. A woman’s peak period of infection with HPV is usually in the first 5–10 years of sexual activity, after which most women have been exposed to and cleared HPV, and developed some immunity against future infection; prevalence across the female population then declines with age.

**What about nonavalent vaccination in those previously vaccinated with the quadrivalent or bivalent vaccine?**

Re-vaccination with the nonavalent vaccine in those who have previously received the quadrivalent or bivalent HPV vaccine is not routinely recommended in Australia or elsewhere. This is because the major benefit of HPV vaccination is derived from effective protection against the two most oncogenic types: HPV 16 and 18. Additionally, the quadrivalent vaccine provides some cross-protection against HPV 31 and the bivalent vaccine provides a high degree of cross-protection against types 31, 33 and 45. The chance of an individual being persistently infected with any one of the five additional HPV types and developing disease or cancer from them is low. It has been estimated that 50% of HPV infections that will ever cause cervical cancer have been acquired by age 20 years and 75% by age 30 years, meaning that the older a woman is at the time of vaccination, the lower her chance of benefitting significantly. Cervical screening remains the most important additional cervical cancer prevention strategy in sexually active women.

Should a previously vaccinated individual wish to receive a nonavalent
vaccine course, a trial found a rate of any injection site reaction of 91%, comparable with studies of vaccine-naïve women, although rates of severe swelling were higher (7.6%). Antibody titres against the additional types are lower than in previously unvaccinated individuals, but the significance of this, if any, is not known.

Key points

- A two-dose HPV vaccine schedule is now in use for individuals aged 14 years or under at the time of the first dose, with a spacing between doses of 6–12 months (and no closer together than six months). It is applicable to all HPV vaccines (bivalent, quadrivalent and nonavalent).
- Those aged 15 years and above at the time of the first dose, or those with significant immunocompromise, require three doses with a dose spacing of zero, two and six months.
- There is never a need to restart an interrupted HPV vaccine course. Any person who received the first dose at the age of 14 years or under, but who has received no further doses, can receive a second and final dose to complete the course as long as the interval between doses is six months or more. Interrupted three-dose courses should adhere to minimum intervals between dose two and three (three months). In fact, the wider the spacing between doses, the better the immune response.
- A course commenced with one HPV vaccine may be completed with another, noting that protection against any HPV types not covered by each dose may be less complete.
- Catch-up HPV vaccination is now available for those aged up to 19 years. Remember to ask older teens who may have missed out at school. If they are unsure of their HPV vaccination status, you can call the HPV register on 1800 478 734 and obtain their vaccination status on the spot.
- Groups for whom HPV vaccine may be of particular benefit, but for whom it is not nationally funded, include:
  - MSM
  - those who are significantly immunocompromised
  - women post treatment for cervical intraepithelial neoplasia.

A second course of HPV vaccination with nonavalent vaccine, in those who have received the quadrivalent or bivalent HPV vaccine, is not routinely recommended. This is because the most substantial benefit of HPV vaccination is achieved through protection against the most oncogenic HPV types 16 and 18, which are common to all three vaccines.

The most important cervical cancer prevention strategy in sexually active women is screening, regardless of their vaccination status.

Useful resources

- Immunise Australia Program HPV information
- HPV register (see ‘useful links’ for infographics summarising nonavalent HPV vaccine for providers and patients): www.hpvregister.org.au
- Cancer Council Australia HPV information site: www.hpvvaccine.org.au

Author

Julia ML Brotherton B Med (Hons), MPH (Hons), GradDipAppEpi, FAFPHM, PhD, GAICD, Medical Director, Registries and Research, Victorian Cytology Service; Honorary Principal Fellow, School of Population and Global Health, University of Melbourne, Vic. jbrother@vcs.org.au

Competing interests: JMLB has been an investigator on investigator-initiated HPV epidemiology studies that have received unrestricted partial funding for laboratory components from Seqirus (cervical cancer typing study) and MSD (recurrent respiratory papillomatosis study) but has never received any personal financial benefits.

Provenance and peer review: Not commissioned, externally peer reviewed.

References


